Degrading JAK2 in ALL by ruxolitinib-based PROTACs

Similar Items

• JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
  by: Junchao Wu, et al.
  Published: (2024-02-01)
• Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib
  by: Maxim Kondratyev, et al.
  Published: (2022-09-01)
• DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
  by: Fenglei Li, et al.
  Published: (2022-11-01)
• Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
  by: M. V. Barabanshchikova, et al.
  Published: (2016-03-01)
• Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
  by: Sinan Ma, et al.
  Published: (2022-07-01)